Pharmaceutical Executive-02-01-2017

Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry

Outlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.

A new approach to reviving industry collaborations.

The key steps to easing rising complexity and cost factors.

Here's to hoping that PhRMA's new public education campaign advances the voice of the patient in its messaging.

Congress is poised to tackle exorbitant drug prices through health reform and FDA legislation.

Recent events you may have missed on the global pharma scene.

With the push toward value-based heathcare set to accelerate even more in 2017, Takeda’s VP of global market access discusses the evolution of this all-important engine for medical innovation and bottom-line returns.

Pharm Exec speaks with Ramita Tandon, executive vice president, ICON Commercialization & Outcomes, about the potential impact of UK and European regulators’ market access plans for the industry.

Despite serving as a regional hub for numerous leading global healthcare and life sciences companies-while simultaneously straddling the frontier of biomedical advancement and innovation-Singapore is reinventing itself yet again and spearheading a new model of Asian healthcare.

Click the title above to open the Pharmaceutical Executive February 2017 issue in an interactive PDF format.

The pursuit of a harmonized European approach to assessing the value of new medicines continues to face roadblocks.